Citadel Advisors
SRGA

Citadel Advisors’s Surgalign Holdings, Inc. Common Stock SRGA Stock Holding History

Citadel Advisors’s Portfolio SRGA Stock Details SRGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-990
Closed -$9K – 14860
2022
Q1 		$9K Buy
+990
New +$15K ﹤0.01% 13397
2021
Q4 		– Sell
-457
Closed -$15K – 15349
2021
Q3 		$15K Sell
457
-1,880
-80% -$68.8K ﹤0.01% 13666
2021
Q2 		$97K Sell
2,337
-523
-18% -$26.8K ﹤0.01% 12949
2021
Q1 		$187K Buy
2,860
+2,233
+356% +$156K ﹤0.01% 11785
2020
Q4 		$41K Sell
627
-1,513
-71% -$98.6K ﹤0.01% 10643
2020
Q3 		$116K Buy
+2,140
New +$164K ﹤0.01% 9184

Other funds holding SRGA

RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
WWP
WR Wealth Planners Columbia, Missouri $311M AUM 18.22% 1-Year Est. Return

Citadel Advisors's SRGA Position: Q3 2023 in Review

Citadel Advisors sold out of Surgalign Holdings, Inc. Common Stock (SRGA) in Q3 2023, closing a stake of 25,840 shares — an estimated $4.73K sold.

Citadel Advisors first reported a position in SRGA in Q2 2013 and held it in 28 quarters. The position peaked at $1.66M in Q2 2015. 4 funds tracked by Wall St. Rank hold SRGA as of Q3 2023.

  • Citadel Advisors reported no remaining Surgalign Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 25,840 Surgalign Holdings, Inc. Common Stock shares in Q3 2023, an estimated $4.73K.
  • Citadel Advisors first reported a position in Surgalign Holdings, Inc. Common Stock in Q2 2013 and held it in 28 quarters.
  • Citadel Advisors's Surgalign Holdings, Inc. Common Stock position peaked at $1.66M in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Surgalign Holdings, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.